Conclusion
metabolic acidosis, PD, hyperkalemia, peritonitis
METABOLIC ACIDOSIS, PERITONITIS
In conclusion, this 24-week prospective cohort study comparing the efficacy of roxadustat and ESAs in PD patients showed the benefit of roxadustat in improving iron metabolism. In addition to its inhibitory effect on hepcidin, roxadustat also induces the expression of molecules required for iron circulation. Thus, the increased iron consumption observed in the roxadustat group may be attributable not only to enhanced hematopoietic production, but also to improved iron utilization efficiency. Information on the differences in the effects of roxadustat and ESAs on iron metabolism could help in selecting appropriate treatment options for PD patients. Roxadustat displayed a manageable safety with no increased risk of the incidence of hyperkalemia, metabolic acidosis and peritonitis.